Hepatitis C: State of Medicaid Access Report Card

Tennessee



Grade	Recommendations to Improve Patient Access		
В	 Remove prior authorization for HCV treatment. Remove additional restrictions as described below. 		

State Overview

As of June 2025, 1,430,912 individuals were enrolled in Medicaid and CHIP. Tennessee has not expanded coverage to low-income adults. It is estimated that as of 2016, 69,100 people were living with HCV in Tennessee. Tennessee Medicaid contracts with three managed care organizations (MCOs): BlueCare, UnitedHealthcare Community Plan, and Wellpoint (formerly Amerigroup).

The Tennessee Medicaid Preferred Drug List includes Epclusa, Mavyret, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir.4

Deductions		Policy		
Prior Authorization	-8	Prior authorization is required for all Direct-Acting Antiviral (DAA) HCV treatment regimens. ⁵		
Fibrosis Restrictions		Tennessee Medicaid does not impose fibrosis restrictions. ⁶		
Substance Use Restrictions		Tennessee Medicaid does not impose substance use restrictions. ⁷		
Prescriber Restrictions		Tennessee Medicaid does not impose prescriber restrictions for most patients. If patients have "a history of HIV, HBC co-infection, prior history with direct acting hepatitis C antivirals, or decompensated cirrhosis" authorization must be requested "by or in consultation with a physician specialist with experience in the treatment of hepatitis C infection (e.g., Hepatology, Infectious Disease or Gastroenterology)."8		
Retreatment Restrictions		Tennessee Medicaid does not impose retreatment restrictions. ⁹		
Access in Managed Care		Tennessee excludes Medicaid pharmacy benefits from MCO contracts, thus all MCOs follow TennCare requirements. ¹⁰		
Additional Restrictions	-4	Tennessee Medicaid imposes additional restrictions as follows ¹¹ : • Documentation of chronic HCV infection. • Documentation of genotype.		
Total Deductions		Total Score [100-Deductions]	Grade	
-12		88	В	

Contact Your State Officials

Medicaid Office¹²: Stephen Smith, Deputy Commissioner and Director of TennCare

310 Great Circle Road, Nashville, TN 37243; Telephone: (800) 342-3145; Email Address: Tenn.Care@tn.gov

Key Sources

Preferred Drug List: TennCare, Preferred Drug List (July 2025)

Clinical Criteria: TennCare, Clinical Criteria, Step Therapy, and Quantity Limits for TennCare Preferred Drug List (PDL) (July 2025))

Prior Authorization Forms: TennCare, Epclusa Prior Authorization Form (Aug. 2024) and TennCare, Mavyret Prior Authorization
Form (Aug. 2025)





- ¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Tennessee, https://perma.cc/ZNG5-V7YZ.
- ² HepVu, Local Data: Tennessee State Profile, https://perma.cc/34US-H34S.
- ³ Division of TennCare, Managed Care Organizations, https://perma.cc/MK2E-8YZQ.
- ⁴ Preferred Drug List.
- ⁵ Preferred Drug List.
- ⁶ Clinical Criteria.
- ⁷ Prior Authorization Forms.
- ⁸ Clinical Criteria.
- ⁹ Clinical Criteria.
- ¹⁰ Kaiser Family Foundation, Annual Medicaid Budget Survey for State Fiscal Years 2023 and 2024, Kaiser Family Foundation (Nov. 14, 2023), https://perma.cc/4K6Y-8DEM.
- ¹¹ Prior Authorization Forms.
- ¹² National Association of Medicaid Directors, Medicaid Directors, https://perma.cc/3E9M-6P56.



